Agile Infectious Disease Solutions
Agilinx Therapeutics was founded in 2018 by a world class team of biotech executives with an outstanding track record in clinical development of infectious disease therapies, to fill a key gap in the early stage clinical development and commercialization life-cycle of infectious disease therapeutics.
Agilinx plans to acquire the rights to key early stage assets from small biotech, big pharma, and academia. Agilinx will then develop these programs rapidly and efficiently to proof-of-concept in humans (typically through Ph IIa) and aim to sell to big biopharma at the optimal point of risk-reward.
Low overhead model – core is executive team, with development engine and valuation expertise unit committed to support company.
Agilinx’s lean, asset-centric business model, focused on rapidly achieving proof of concept in humans, is designed to achieve a shortened commercial payback of 2-3 years.
Agilinx is actively seeking to in-license both small molecule and biologic compounds in the following areas:
Antiviral (especially HBV/HCV/HIV)
Please reach out to us at to discuss potential licensing opportunities for your early stage or under-resourced candidates in the above categories.